NCT07334301 2026-01-12
BEACON2
University of Birmingham
Phase 1/2 Recruiting
Clinical Trials
6 trialsNCT02308527 2024-05-14
BEACON
University of Birmingham
Phase 2 Active not recruiting
NCT00885326 2023-04-10
N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Completed
NCT01114555 2019-11-21
Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01492673 2019-10-29
Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00450827 2015-09-28
Iodine I 131 Monoclonal Antibody 3F8 and Bevacizumab in Treating Patients With Relapsed or Refractory Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 1 Completed